Agios Pharmaceuticals (AGIO) Financials

$26.98 -0.23 (-0.85%)

Closing price 05/6/2026 04:00 PM Eastern

Extended Trading

$27.00 +0.02 (+0.08%)

As of 04:46 AM Eastern

Annual Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-118	-198	-315	-346	-411	-327	1,605	-232	-352	674	-413
Consolidated Net Income / (Loss)	-118	-198	-315	-346	-411	-327	1,605	-232	-352	674	-413
Net Income / (Loss) Continuing Operations	-118	-198	-315	-346	-301	-329	-357	-232	-352	680	-411
Total Pre-Tax Income	-118	-198	-315	-346	-301	-329	-357	-232	-352	718	-414
Total Operating Income	-119	-201	-321	-362	-316	-336	-378	-389	-391	-426	-472
Total Gross Profit	59	70	43	93	0.00	0.00	0.00	13	24	32	48
Total Revenue	59	70	43	94	0.00	0.00	0.00	14	27	36	54
Operating Revenue	59	70	43	94	-	-	0.00	14	27	36	54
Total Cost of Revenue	0.00	0.00	0.00	1.40	0.00	0.00	0.00	1.70	2.88	4.17	6.35
Operating Cost of Revenue	-	0.00	0.00	1.40	-	-	0.00	1.70	2.88	4.17	6.35
Total Operating Expenses	178	271	364	455	316	336	378	402	415	458	520
Selling, General & Admin Expense	36	51	71	114	102	115	121	122	120	157	180
Research & Development Expense	142	220	293	341	214	221	257	280	296	301	340
Total Other Income / (Expense), net	0.97	2.51	6.12	16	15	6.61	22	157	39	1,137	56
Interest & Investment Income	0.97	2.51	6.12	16	15	6.61	7.48	23	33	48	56
Other Income / (Expense), net	-	-	-	-	-	0.00	14	135	6.06	1,089	0.00
Income Tax Expense	-	-	-	-	-	-	-	0.00	0.00	44	-1.02
Other Gains / (Losses), net	-	-	-	-	0.00	-	-	-	-	6.49	1.96
Basic Earnings per Share	($3.15)	($5.07)	($6.75)	($6.03)	($6.86)	($4.74)	$26.55	($4.23)	($6.33)	$11.86	($7.12)
Weighted Average Basic Shares Outstanding	37.43M	39.13M	46.59M	57.42M	59.99M	69.00M	60.45M	54.79M	55.65M	56.81M	57.97M
Diluted Earnings per Share	($3.15)	($5.07)	($6.75)	($6.03)	($6.86)	($4.74)	$26.55	($4.23)	($6.33)	$11.64	($7.12)
Weighted Average Diluted Shares Outstanding	37.43M	39.13M	46.59M	57.42M	59.99M	69.00M	60.45M	54.79M	55.65M	57.89M	57.97M
Weighted Average Basic & Diluted Shares Outstanding	37.43M	39.13M	46.59M	57.42M	59.99M	69.00M	54.64M	55.29M	56.19M	57.30M	58.59M

This table shows Agios Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-91	-96	-82	-96	948	-97	-89	-112	-103	-108	-99
Consolidated Net Income / (Loss)	-91	-96	-82	-96	948	-97	-89	-112	-103	-108	-99
Net Income / (Loss) Continuing Operations	-91	-96	-82	-96	950	-92	-89	-112	-103	-106	-99
Total Pre-Tax Income	-91	-96	-83	-98	1,001	-104	-89	-113	-103	-107	-99
Total Operating Income	-101	-106	-92	-106	-103	-125	-107	-127	-117	-122	-110
Total Gross Profit	6.77	6.52	7.56	7.12	8.18	9.47	7.64	11	11	18	19
Total Revenue	7.40	7.10	8.19	8.62	8.96	11	8.73	12	13	20	21
Operating Revenue	7.40	7.10	8.19	8.62	8.96	11	8.73	12	13	20	21
Total Cost of Revenue	0.63	0.59	0.63	1.50	0.78	1.26	1.09	1.70	1.68	1.88	1.32
Operating Cost of Revenue	0.63	0.59	0.63	1.50	0.78	1.26	1.09	1.70	1.68	1.88	1.32
Total Operating Expenses	108	113	100	113	111	135	114	138	128	140	129
Selling, General & Admin Expense	26	35	31	36	39	52	42	46	41	52	48
Research & Development Expense	82	77	69	77	72	83	73	92	87	88	81
Total Other Income / (Expense), net	9.57	10	8.89	8.12	1,102	16	17	15	13	12	11
Interest & Investment Income	8.38	8.62	8.89	8.12	13	18	16	15	13	12	11
Other Income / (Expense), net	1.20	1.71	-	-	1,089	-	1.25	-	0.00	-	0.12
Basic Earnings per Share	($1.64)	($1.71)	($1.45)	($1.69)	$16.65	($1.65)	($1.55)	($1.93)	($1.78)	($1.86)	($1.69)
Weighted Average Basic Shares Outstanding	55.80M	55.65M	56.38M	56.80M	56.94M	56.81M	57.46M	57.93M	58.14M	57.97M	58.78M
Diluted Earnings per Share	($1.64)	($1.71)	($1.45)	($1.69)	$16.22	($1.44)	($1.55)	($1.93)	($1.78)	($1.86)	($1.69)
Weighted Average Diluted Shares Outstanding	55.80M	55.65M	56.38M	56.80M	58.43M	57.89M	57.46M	57.93M	58.14M	57.97M	58.78M
Weighted Average Basic & Diluted Shares Outstanding	55.89M	56.19M	56.77M	56.89M	57.03M	57.30M	57.92M	58.10M	58.31M	58.59M	59.47M

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	58	89	-58	-32	10	47	76	-64	-51	-12	13
Net Cash From Operating Activities	-77	39	-285	-304	-371	-291	-407	-309	-296	-390	-373
Net Cash From Continuing Operating Activities	-77	39	-285	-304	-236	-244	-314	-309	-296	-390	-373
Net Income / (Loss) Continuing Operations	-118	-198	-315	-346	-301	-329	-357	-232	-352	674	-413
Consolidated Net Income / (Loss)	-118	-198	-315	-346	-411	-327	1,605	-232	-352	674	-413
Depreciation Expense	3.34	5.70	6.43	7.17	8.09	9.79	9.24	8.56	6.62	5.65	5.18
Amortization Expense	0.54	0.77	-0.01	-3.84	-3.20	3.02	6.95	-1.20	-5.05	-14	-7.20
Non-Cash Adjustments To Reconcile Net Income	30	45	49	67	61	71	63	-69	60	-1,050	58
Changes in Operating Assets and Liabilities, net	6.64	185	-26	-28	-0.41	1.97	-37	-16	-5.39	-4.76	-16
Net Cash From Investing Activities	128	-119	-58	-274	91	76	1,249	243	240	363	377
Net Cash From Continuing Investing Activities	128	-119	-58	-274	92	77	-554	243	240	363	377
Purchase of Property, Plant & Equipment	-20	-9.92	-4.63	-6.99	-12	-14	-5.74	-4.88	-1.00	-1.69	-4.32
Purchase of Investments	-353	-506	-689	-933	-489	-557	-1,378	-1,031	-418	-1,542	-642
Sale of Property, Plant & Equipment	-	-	-	-	-	0.00	0.00	0.96	1.33	0.04	0.00
Divestitures	-	-	-	-	-	-	-	0.00	0.00	200	0.00
Sale and/or Maturity of Investments	502	397	635	666	592	648	830	1,146	675	818	1,033
Other Investing Activities, net	-	-	-	-	-	0.00	0.00	132	-18	889	-10
Net Cash From Financing Activities	6.37	170	285	546	290	262	-766	2.35	5.43	14	8.68
Net Cash From Continuing Financing Activities	6.37	170	285	546	290	11	-766	2.35	5.43	14	8.68
Issuance of Common Equity	6.58	170	284	547	290	11	37	2.68	5.43	14	8.68
Cash Income Taxes Paid	-	-	-	-	0.00	0.00	16	0.00	1.57	43	0.63

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-20	24	31	-34	169	-177	2.72	1.91	12	-3.58	24
Net Cash From Operating Activities	-62	-72	-100	-73	-84	-133	-111	-77	-88	-96	-119
Net Cash From Continuing Operating Activities	-62	-72	-100	-73	-84	-133	-111	-77	-88	-96	-119
Net Income / (Loss) Continuing Operations	-91	-96	-82	-96	948	-97	-89	-112	-103	-108	-99
Consolidated Net Income / (Loss)	-91	-96	-82	-96	948	-97	-89	-112	-103	-108	-99
Depreciation Expense	1.62	1.40	1.35	1.59	1.35	1.37	1.28	1.26	1.37	1.27	1.36
Amortization Expense	1.08	-0.39	-2.53	-2.61	-3.73	-5.62	-1.35	-2.42	-1.67	-1.75	-1.14
Non-Cash Adjustments To Reconcile Net Income	20	13	8.20	18	-1,086	10	10	20	12	13	14
Changes in Operating Assets and Liabilities, net	7.46	9.10	-25	6.48	57	-42	-32	17	4.01	-0.28	-34
Net Cash From Investing Activities	39	96	125	37	251	-49	113	79	96	90	141
Net Cash From Continuing Investing Activities	39	96	125	37	251	-49	113	79	96	90	141
Purchase of Property, Plant & Equipment	-0.37	-0.23	-0.14	-0.16	-0.42	-0.97	-0.77	-0.88	-1.56	-1.12	-0.77
Purchase of Investments	-95	-90	-244	-105	-996	-198	-175	-131	-175	-161	-148
Sale and/or Maturity of Investments	151	186	369	142	158	150	288	221	272	252	290
Net Cash From Financing Activities	1.88	0.85	5.86	1.10	2.64	4.84	1.62	0.07	4.44	2.56	2.08
Net Cash From Continuing Financing Activities	1.88	0.85	5.86	1.10	2.64	4.84	1.62	0.07	4.44	2.56	2.08
Issuance of Common Equity	1.88	0.85	5.86	1.10	2.64	4.84	1.62	0.07	4.44	2.56	2.08
Cash Income Taxes Paid	0.79	-0.02	-0.53	-0.08	-0.03	44	0.19	1.32	0.07	-0.94	0.00

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	420	619	614	858	891	853	1,438	1,239	937	1,663	1,297
Total Current Assets	337	560	445	614	612	637	1,064	833	834	966	942
Cash & Equivalents	72	161	103	71	81	127	203	139	88	76	89
Short-Term Investments	245	381	321	515	484	445	817	644	689	817	765
Accounts Receivable	12	3.43	0.00	5.08	8.95	0.00	4.38	2.21	2.81	4.11	11
Inventories, net	-	-	0.00	0.87	7.33	-	0.00	8.49	19	28	33
Prepaid Expenses	8.73	10	18	17	24	16	40	39	35	40	44
Plant, Property, & Equipment, net	23	25	24	24	31	31	29	23	15	12	11
Total Noncurrent Assets	60	34	145	220	248	185	345	383	88	686	344
Long-Term Investments	59	32	144	220	153	98	266	314	29	638	310
Other Noncurrent Operating Assets	0.61	1.62	0.89	0.24	94	85	78	69	58	48	34
Total Liabilities & Shareholders' Equity	420	619	614	858	891	853	1,438	1,239	937	1,663	1,297
Total Liabilities	75	261	239	171	250	453	146	138	126	122	104
Total Current Liabilities	53	88	95	94	93	94	60	63	68	81	82
Accounts Payable	15	17	23	18	22	18	17	19	9.78	17	18
Accrued Expenses	16	32	34	42	53	31	32	30	43	47	45
Other Current Liabilities	-	-	38	33	6.92	7.41	11	14	15	17	18
Total Noncurrent Liabilities	22	172	144	77	157	359	86	75	58	41	22
Other Noncurrent Operating Liabilities	-	-	126	60	106	97	86	75	58	41	22
Total Equity & Noncontrolling Interests	345	359	376	688	641	400	1,292	1,101	811	1,541	1,193
Total Preferred & Common Equity	345	359	376	688	641	400	1,292	1,101	811	1,541	1,193
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Common Equity	345	359	376	688	641	400	1,292	1,101	811	1,541	1,193
Common Stock	630	842	1,175	1,794	2,156	2,243	2,334	2,386	2,437	2,494	2,555
Retained Earnings	-285	-483	-798	-1,105	-1,516	-1,843	-239	-471	-823	-149	-562
Treasury Stock	-	-	-	-	-	0.00	-802	-802	-802	-802	-802
Accumulated Other Comprehensive Income / (Loss)	-0.32	-0.31	-1.39	-2.17	0.20	0.11	-1.20	-13	-0.44	-1.52	2.19

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,180	1,151	1,085	1,007	850	773	1,792	1,556	1,471	1,386	1,185
Total Current Assets	785	792	757	704	664	632	1,074	969	1,019	1,033	835
Cash & Equivalents	122	104	85	64	119	85	254	79	81	93	114
Short-Term Investments	605	635	618	583	479	485	751	814	858	860	623
Accounts Receivable	5.59	1.78	2.25	1.18	3.45	3.76	3.12	3.34	4.99	5.03	16
Inventories, net	5.18	11	16	17	23	24	26	30	31	32	35
Prepaid Expenses	46	39	37	38	39	35	40	42	45	43	47
Plant, Property, & Equipment, net	25	21	20	17	14	13	12	11	11	11	11
Total Noncurrent Assets	370	338	308	286	172	128	706	576	441	342	340
Long-Term Investments	298	272	244	225	116	75	656	531	400	304	308
Other Noncurrent Operating Assets	72	66	64	61	56	53	50	45	41	38	31
Total Liabilities & Shareholders' Equity	1,180	1,151	1,085	1,007	850	773	1,792	1,556	1,471	1,386	1,185
Total Liabilities	130	115	121	120	106	113	165	89	102	101	76
Total Current Liabilities	54	45	55	58	52	63	119	52	70	75	59
Accounts Payable	10	8.66	12	13	11	10	17	14	18	20	14
Accrued Expenses	30	22	29	30	25	37	33	21	35	37	26
Other Current Liabilities	13	14	14	15	15	16	16	17	18	18	19
Total Noncurrent Liabilities	77	70	66	62	54	50	46	37	31	27	17
Other Noncurrent Operating Liabilities	77	70	66	62	54	50	46	37	31	27	17
Total Equity & Noncontrolling Interests	1,050	1,037	964	887	744	661	1,627	1,467	1,370	1,284	1,109
Total Preferred & Common Equity	1,050	1,037	964	887	744	661	1,627	1,467	1,370	1,284	1,109
Preferred Stock	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,050	1,037	964	887	744	661	1,627	1,467	1,370	1,284	1,109
Common Stock	2,375	2,399	2,411	2,422	2,452	2,464	2,478	2,507	2,522	2,538	2,573
Retained Earnings	-507	-552	-635	-727	-904	-1,000	-52	-238	-350	-454	-661
Treasury Stock	-802	-802	-802	-802	-802	-802	-802	-802	-802	-802	-802
Accumulated Other Comprehensive Income / (Loss)	-15	-8.41	-8.87	-5.90	-1.09	-1.05	3.42	0.37	0.66	2.05	-0.31

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-9.55%	18.22%	-38.46%	119.45%	-100.00%	0.00%	0.00%	0.00%	88.36%	36.07%	48.03%
EBITDA Growth	-119.84%	-69.41%	-61.62%	-14.24%	13.30%	-3.77%	-7.64%	28.96%	-55.36%	270.52%	-172.44%
EBIT Growth	-119.27%	-69.32%	-59.61%	-12.99%	12.75%	-6.21%	-8.36%	30.09%	-51.48%	272.12%	-171.17%
NOPAT Growth	-119.27%	-69.32%	-59.61%	-12.99%	12.75%	-6.21%	-12.65%	-2.81%	-0.63%	-45.78%	17.27%
Net Income Growth	-120.04%	-68.58%	-58.55%	-9.97%	-18.91%	20.44%	590.18%	-114.45%	-51.89%	291.35%	-161.27%
EPS Growth	-98.11%	-60.95%	-33.14%	10.67%	-13.76%	30.90%	660.13%	-115.93%	-49.65%	283.89%	-161.17%
Operating Cash Flow Growth	-29.65%	150.11%	-839.67%	-6.73%	-21.75%	21.55%	-40.09%	24.02%	4.34%	-31.68%	4.33%
Free Cash Flow Firm Growth	-65.03%	145.60%	-668.54%	-32.68%	19.94%	-10.52%	-0.65%	7.49%	-1.69%	-46.89%	13.26%
Invested Capital Growth	28.53%	-598.21%	10.57%	38.68%	35.02%	72.01%	127.33%	-34.77%	21.85%	91.69%	221.30%
Revenue Q/Q Growth	-12.46%	30.73%	-23.00%	27.25%	-100.00%	100.00%	0.00%	43.40%	11.62%	11.03%	20.62%
EBITDA Q/Q Growth	-13.22%	-8.85%	-11.75%	-2.05%	24.57%	-36.80%	-1.56%	35.56%	0.02%	259.44%	1.50%
EBIT Q/Q Growth	-13.56%	-8.95%	-11.36%	-1.75%	24.11%	-36.30%	-1.41%	35.53%	-0.27%	263.01%	0.73%
NOPAT Q/Q Growth	-13.56%	-8.95%	-11.36%	-1.75%	24.11%	-36.30%	-5.43%	1.43%	-1.85%	1.84%	0.73%
Net Income Q/Q Growth	-13.45%	-8.69%	-11.24%	-1.02%	-2.63%	1.41%	0.19%	36.13%	-60.32%	-0.09%	-2.87%
EPS Q/Q Growth	-12.10%	-5.41%	-7.31%	3.83%	-0.15%	3.66%	17.63%	-80.77%	-60.66%	2.37%	-6.27%
Operating Cash Flow Q/Q Growth	-41.99%	-34.92%	-8.87%	0.09%	-5.53%	13.20%	-9.31%	5.48%	-2.18%	-18.43%	9.01%
Free Cash Flow Firm Q/Q Growth	-34.38%	-27.13%	-7.11%	-1.54%	17.33%	-1,177.58%	40.59%	10.46%	-5.97%	-12.61%	11.11%
Invested Capital Q/Q Growth	4.76%	2.79%	-0.17%	0.26%	16.90%	91.14%	508.51%	-84.17%	-67.79%	126.27%	5.70%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	98.52%	0.00%	0.00%	0.00%	88.03%	89.26%	88.59%	88.26%
EBITDA Margin	-194.22%	-278.30%	-730.91%	-380.50%	0.00%	0.00%	0.00%	-1,735.11%	-1,431.09%	1,793.43%	-877.60%
Operating Margin	-200.78%	-287.57%	-745.84%	-384.03%	0.00%	0.00%	0.00%	-2,732.07%	-1,459.52%	-1,166.47%	-873.87%
EBIT Margin	-200.78%	-287.57%	-745.84%	-384.03%	0.00%	0.00%	0.00%	-1,786.83%	-1,436.95%	1,817.63%	-873.87%
Profit (Net Income) Margin	-199.14%	-283.97%	-731.60%	-366.61%	0.00%	0.00%	0.00%	-1,627.82%	-1,312.63%	1,845.92%	-764.01%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	136.52%	99.41%	-450.12%	100.00%	100.00%	93.84%	99.75%
Interest Burden Percent	99.18%	98.75%	98.09%	95.46%	95.30%	98.03%	97.95%	91.10%	91.35%	108.23%	87.64%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.16%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,627.29%	-6,465.52%	-5,883.24%	-1,757.89%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,630.70%	-6,457.32%	-5,975.03%	-1,751.79%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5,607.92%	6,428.68%	5,940.53%	1,727.70%
Return on Equity (ROE)	-30.60%	-56.41%	-85.73%	-65.10%	-61.97%	-62.95%	189.74%	-19.38%	-36.83%	57.29%	-30.20%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,987.86%	-5,585.20%	-6,485.22%	-5,946.11%	-1,862.95%
Operating Return on Assets (OROA)	-26.03%	-38.68%	-52.01%	-49.22%	0.00%	0.00%	0.00%	-19.01%	-35.43%	51.02%	-31.90%
Return on Assets (ROA)	-25.82%	-38.20%	-51.02%	-46.99%	0.00%	0.00%	0.00%	-17.32%	-32.36%	51.82%	-27.89%
Return on Common Equity (ROCE)	-30.60%	-56.41%	-85.73%	-65.10%	-61.97%	-62.95%	189.74%	-19.38%	-36.83%	57.29%	-30.20%
Return on Equity Simple (ROE_SIMPLE)	-34.11%	-55.35%	-83.80%	-50.33%	-64.24%	-81.94%	124.21%	-21.06%	-43.41%	43.72%	0.00%
Net Operating Profit after Tax (NOPAT)	-83	-141	-225	-254	-221	-235	-265	-272	-274	-400	-330
NOPAT Margin	-140.55%	-201.30%	-522.09%	-268.82%	0.00%	0.00%	0.00%	-1,912.45%	-1,021.66%	-1,094.58%	-611.71%
Net Nonoperating Expense Percent (NNEP)	-8.22%	-12.17%	-15.79%	-13.44%	-24.97%	-16.21%	219.04%	3.40%	-8.20%	91.79%	-6.10%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-24.74%	-33.79%	-25.93%	-27.70%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	1.48%	0.00%	0.00%	0.00%	11.97%	10.74%	11.41%	11.74%
SG&A Expenses to Revenue	60.88%	72.56%	165.36%	120.93%	0.00%	0.00%	0.00%	854.45%	447.02%	429.57%	333.68%
R&D to Revenue	239.90%	315.00%	680.48%	361.62%	0.00%	0.00%	0.00%	1,965.66%	1,101.76%	825.49%	628.44%
Operating Expenses to Revenue	300.78%	387.57%	845.84%	482.55%	0.00%	0.00%	0.00%	2,820.11%	1,548.78%	1,255.06%	962.12%
Earnings before Interest and Taxes (EBIT)	-119	-201	-321	-362	-316	-336	-364	-254	-385	663	-472
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-115	-195	-314	-359	-311	-323	-348	-247	-384	655	-474
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.08	4.89	7.42	3.90	4.39	7.51	1.38	1.40	1.53	1.22	1.33
Price to Tangible Book Value (P/TBV)	7.08	4.89	7.42	3.90	4.39	7.51	1.38	1.40	1.53	1.22	1.33
Price to Revenue (P/Rev)	41.33	25.09	64.80	28.42	0.00	0.00	0.00	108.35	46.40	51.35	29.38
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	1.11	0.00	0.00	2.78	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	89.89%	0.00%	0.00%	35.95%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	85.18	116.69	94.14	38.32	14.75
Enterprise Value to Revenue (EV/Rev)	34.98	16.88	51.60	19.89	0.00	0.00	0.00	31.31	16.34	9.37	7.83
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.52	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	30.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	27.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.10	-1.35	-1.55	-1.29	-1.15	-1.09	-1.01	-1.00	-1.00	-0.99	-0.99
Leverage Ratio	1.19	1.48	1.68	1.39	1.32	1.68	1.35	1.12	1.14	1.11	1.08
Compound Leverage Factor	1.18	1.46	1.65	1.32	1.26	1.64	1.33	1.02	1.04	1.20	0.95
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.11%	0.08%	0.02%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.11%	0.08%	0.02%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	99.90%	99.92%	99.98%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	2.30	2.07	3.70	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	3.24	2.85	4.86	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	18.63	2.90	4.21	7.06	3.89	0.41	7.12	6.26	4.35	11.05	8.18
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.38	6.33	4.69	6.56	6.59	6.74	17.79	13.30	12.27	11.90	11.46
Quick Ratio	6.21	6.16	4.47	6.31	6.18	6.07	17.12	12.54	11.47	11.06	10.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-95	43	-247	-328	-263	-290	-292	-270	-275	-404	-350
Operating Cash Flow to CapEx	-381.62%	388.93%	-6,164.51%	-4,357.59%	-3,081.33%	-2,061.24%	-7,094.93%	-7,900.89%	0.00%	-23,698.54%	-8,641.73%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.13	0.07	0.13	0.00	0.00	0.00	0.01	0.02	0.03	0.04
Accounts Receivable Turnover	5.79	9.30	0.00	0.00	0.00	0.00	0.00	4.33	10.70	10.55	7.36
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.21	0.18	0.21
Fixed Asset Turnover	3.99	2.88	1.73	3.87	0.00	0.00	0.00	0.55	1.40	2.70	4.81
Accounts Payable Turnover	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.10	0.20	0.32	0.36
Days Sales Outstanding (DSO)	63.05	39.24	0.00	0.00	0.00	0.00	0.00	84.38	34.13	34.60	49.61
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,746.32	2,045.93	1,741.19
Days Payable Outstanding (DPO)	0.00	0.00	0.00	5,310.01	0.00	0.00	0.00	3,782.38	1,798.77	1,157.79	1,006.64
Cash Conversion Cycle (CCC)	63.05	39.24	0.00	-5,310.01	0.00	0.00	0.00	-3,698.00	-18.32	922.73	784.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-31	-215	-192	-118	-77	-21	5.86	3.82	4.66	8.93	29
Invested Capital Turnover	-1.60	-0.57	-0.21	-0.61	0.00	0.00	0.00	2.94	6.33	5.37	2.87
Increase / (Decrease) in Invested Capital	12	-184	23	74	41	55	27	-2.04	0.84	4.27	20
Enterprise Value (EV)	2,068	1,180	2,220	1,877	2,095	2,331	499	446	438	342	423
Market Capitalization	2,444	1,753	2,787	2,683	2,812	3,001	1,785	1,543	1,245	1,874	1,587
Book Value per Share	$9.17	$8.53	$7.70	$11.82	$10.88	$5.77	$23.79	$20.03	$14.51	$27.02	$20.46
Tangible Book Value per Share	$9.17	$8.53	$7.70	$11.82	$10.88	$5.77	$23.79	$20.03	$14.51	$27.02	$20.46
Total Capital	345	359	376	688	641	400	1,292	1,101	811	1,541	1,193
Total Debt	0.00	0.00	0.00	0.00	0.67	0.33	0.28	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.67	0.33	0.28	0.00	0.00	0.00	0.00
Net Debt	-376	-574	-568	-805	-717	-670	-1,286	-1,097	-806	-1,532	-1,164
Capital Expenditures (CapEx)	20	9.92	4.63	6.99	12	14	5.74	3.92	-0.33	1.65	4.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-33	-70	-74	-65	-46	-31	-16	-13	-11	-9.27	5.42
Debt-free Net Working Capital (DFNWC)	284	471	350	520	519	542	1,004	770	766	884	860
Net Working Capital (NWC)	284	471	350	520	519	542	1,004	770	766	884	860
Net Nonoperating Expense (NNE)	35	58	90	92	190	92	-1,870	-41	78	-1,073	82
Net Nonoperating Obligations (NNO)	-376	-574	-568	-805	-717	-421	-1,286	-1,097	-806	-1,532	-1,164
Total Depreciation and Amortization (D&A)	3.88	6.47	6.42	3.34	4.89	13	16	7.37	1.57	-8.83	-2.02
Debt-free, Cash-free Net Working Capital to Revenue	-55.08%	-99.95%	-171.16%	-68.89%	0.00%	0.00%	0.00%	-91.12%	-41.19%	-25.39%	10.03%
Debt-free Net Working Capital to Revenue	481.13%	674.55%	814.49%	551.22%	0.00%	0.00%	0.00%	5,408.31%	2,855.31%	2,423.27%	1,591.48%
Net Working Capital to Revenue	481.13%	674.55%	814.49%	551.22%	0.00%	0.00%	0.00%	5,408.31%	2,855.31%	2,423.27%	1,591.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.15)	($5.07)	($6.75)	($6.03)	($6.86)	($4.74)	$26.55	($4.23)	($6.33)	$11.86	($7.12)
Adjusted Weighted Average Basic Shares Outstanding	37.85M	42.23M	57.33M	58.40M	68.51M	69.60M	60.45M	54.79M	55.65M	56.81M	57.97M
Adjusted Diluted Earnings per Share	($3.15)	($5.07)	($6.75)	($6.03)	($6.86)	($4.74)	$26.55	($4.23)	($6.33)	$11.64	($7.12)
Adjusted Weighted Average Diluted Shares Outstanding	37.85M	42.23M	57.33M	58.40M	68.51M	69.60M	60.45M	54.79M	55.65M	57.89M	57.97M
Adjusted Basic & Diluted Earnings per Share	($3.15)	($5.07)	($6.75)	($6.03)	($6.86)	($4.74)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.43M	39.13M	46.59M	57.42M	59.99M	69.00M	54.64M	55.29M	56.19M	57.30M	58.59M
Normalized Net Operating Profit after Tax (NOPAT)	-83	-141	-225	-254	-221	-235	-265	-272	-274	-400	-330
Normalized NOPAT Margin	-140.55%	-201.30%	-522.09%	-268.82%	0.00%	0.00%	0.00%	-1,912.45%	-1,021.66%	-1,094.58%	-611.71%
Pre Tax Income Margin	-199.14%	-283.97%	-731.60%	-366.61%	0.00%	0.00%	0.00%	-1,627.82%	-1,312.63%	1,967.15%	-765.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.18%	0.00%	0.00%	0.00%	0.00%	0.00%	50.01%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	58,592,172.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	58,592,172.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-1.69
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	110.44%	64.80%	46.00%	28.35%	21.15%	51.06%	6.56%	44.57%	43.69%	86.09%	137.75%
EBITDA Growth	-9.37%	-4.31%	-3.50%	-12.92%	1,114.41%	-24.85%	-14.42%	-20.02%	-111.91%	5.59%	-4.02%
EBIT Growth	-10.77%	-5.44%	-3.33%	-13.23%	1,089.30%	-19.58%	-15.81%	-20.07%	-111.85%	2.77%	-4.30%
NOPAT Growth	-10.77%	24.99%	-1.61%	-12.93%	-37.84%	-17.65%	-15.81%	-20.07%	15.97%	2.77%	-3.18%
Net Income Growth	-11.72%	-362.66%	-0.66%	-14.69%	1,137.97%	-0.61%	-9.49%	-16.54%	-110.91%	-11.93%	-11.00%
EPS Growth	-10.07%	-351.47%	1.36%	-11.92%	1,089.02%	15.79%	-6.90%	-14.20%	-110.97%	-29.17%	-9.03%
Operating Cash Flow Growth	13.61%	-9.56%	-4.92%	-8.75%	-36.62%	-83.71%	-11.64%	-6.25%	-4.67%	27.75%	-6.67%
Free Cash Flow Firm Growth	31.78%	22.55%	-12.89%	-22.01%	19.71%	-22.02%	-26.91%	-44.33%	-192.08%	-14.23%	-13.61%
Invested Capital Growth	-40.12%	21.85%	15.75%	-12.12%	-335.07%	91.69%	41.41%	98.18%	179.85%	221.30%	51.84%
Revenue Q/Q Growth	10.24%	-4.00%	15.29%	5.20%	4.05%	19.70%	-18.68%	42.73%	3.41%	55.02%	3.90%
EBITDA Q/Q Growth	-4.06%	-6.76%	9.95%	-12.87%	1,034.82%	-113.14%	17.47%	-20.17%	8.62%	-4.18%	10.14%
EBIT Q/Q Growth	-8.30%	-4.88%	11.95%	-13.21%	1,046.22%	-112.68%	14.72%	-19.16%	8.02%	-4.03%	9.60%
NOPAT Q/Q Growth	-7.68%	-5.33%	13.37%	-14.93%	-31.43%	10.10%	14.72%	-19.16%	8.02%	-4.03%	9.50%
Net Income Q/Q Growth	-8.97%	-5.05%	15.00%	-17.87%	1,086.20%	-110.18%	7.49%	-25.46%	7.67%	-4.45%	8.26%
EPS Q/Q Growth	-8.61%	-4.27%	15.20%	-16.55%	1,059.76%	-108.88%	-7.64%	-24.52%	7.77%	-4.49%	9.14%
Operating Cash Flow Q/Q Growth	7.65%	-17.59%	-37.77%	27.31%	-16.02%	-58.12%	16.28%	30.82%	-14.30%	-9.15%	-23.60%
Free Cash Flow Firm Q/Q Growth	-3.32%	-23.44%	8.97%	-5.10%	32.02%	-87.61%	5.32%	-19.52%	-37.58%	26.63%	5.83%
Invested Capital Q/Q Growth	-16.52%	-67.79%	536.38%	-48.65%	-323.31%	126.27%	369.47%	-28.04%	-10.02%	5.70%	121.87%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.44%	91.75%	92.34%	82.65%	91.27%	88.26%	87.57%	86.33%	86.96%	90.59%	93.64%
EBITDA Margin	-1,310.93%	-1,457.89%	-1,138.73%	-1,221.75%	10,976.53%	-1,204.90%	-1,222.77%	-1,029.44%	-909.70%	-611.33%	-528.71%
Operating Margin	-1,363.66%	-1,496.23%	-1,124.34%	-1,228.29%	-1,146.93%	-1,165.30%	-1,221.97%	-1,020.12%	-907.37%	-608.89%	-530.34%
EBIT Margin	-1,347.47%	-1,472.11%	-1,124.34%	-1,209.96%	11,003.18%	-1,165.30%	-1,221.97%	-1,020.12%	-907.37%	-608.89%	-529.77%
Profit (Net Income) Margin	-1,234.27%	-1,350.70%	-995.84%	-1,115.71%	10,574.69%	-899.56%	-1,023.25%	-899.40%	-803.05%	-541.09%	-477.74%
Tax Burden Percent	100.00%	100.00%	98.04%	100.00%	94.69%	93.02%	98.62%	99.54%	100.00%	100.71%	100.00%
Interest Burden Percent	91.60%	91.75%	90.35%	92.21%	101.49%	82.99%	84.91%	88.58%	88.50%	88.24%	90.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	5.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1,188.78%	-6,628.12%	-838.03%	-1,655.05%	0.00%	-4,384.34%	-885.75%	-1,286.82%	0.00%	-1,224.87%	-464.73%
ROIC Less NNEP Spread (ROIC-NNEP)	-1,186.60%	-6,625.86%	-836.04%	-1,652.28%	0.00%	-4,383.57%	-884.38%	-1,284.49%	0.00%	-1,223.17%	-462.94%
Return on Net Nonoperating Assets (RNNOA)	1,162.96%	6,596.48%	810.11%	1,619.21%	0.00%	4,358.26%	855.76%	1,255.79%	0.00%	1,206.35%	443.97%
Return on Equity (ROE)	-25.82%	-31.64%	-27.92%	-35.85%	53.65%	-26.08%	-29.99%	-31.03%	-27.57%	-18.52%	-20.76%
Cash Return on Invested Capital (CROIC)	-1,344.26%	-6,485.22%	-1,010.70%	-1,730.53%	0.00%	-5,946.11%	-1,265.38%	-2,100.61%	-1,452.38%	-1,862.95%	-672.07%
Operating Return on Assets (OROA)	-29.60%	-36.30%	-33.04%	-40.77%	258.43%	-32.71%	-37.63%	-37.16%	-25.58%	-22.22%	-25.54%
Return on Assets (ROA)	-27.12%	-33.30%	-29.27%	-37.59%	248.37%	-25.25%	-31.51%	-32.76%	-22.64%	-19.75%	-23.03%
Return on Common Equity (ROCE)	-25.82%	-31.64%	-27.92%	-35.85%	53.65%	-26.08%	-29.99%	-31.03%	-27.57%	-18.52%	-20.76%
Return on Equity Simple (ROE_SIMPLE)	-24.76%	0.00%	-47.40%	-55.25%	41.45%	0.00%	45.41%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-71	-74	-64	-74	-97	-88	-75	-89	-82	-85	-77
NOPAT Margin	-954.56%	-1,047.36%	-787.04%	-859.80%	-1,086.07%	-815.71%	-855.38%	-714.08%	-635.16%	-426.23%	-371.24%
Net Nonoperating Expense Percent (NNEP)	-2.18%	-2.26%	-1.98%	-2.77%	82.53%	-0.77%	-1.37%	-2.33%	-1.48%	-1.70%	-1.79%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.17%	-	-	-	-5.68%	-5.09%	-6.49%	-6.37%	-7.13%	-6.94%
Cost of Revenue to Revenue	8.56%	8.25%	7.66%	17.35%	8.73%	11.74%	12.43%	13.67%	13.04%	9.41%	6.36%
SG&A Expenses to Revenue	348.99%	497.04%	378.73%	412.49%	429.91%	481.80%	475.90%	368.28%	320.45%	258.48%	232.84%
R&D to Revenue	1,106.11%	1,090.93%	837.95%	898.44%	808.29%	771.76%	833.64%	738.18%	673.88%	441.01%	391.15%
Operating Expenses to Revenue	1,455.10%	1,587.98%	1,216.68%	1,310.93%	1,238.20%	1,253.56%	1,309.53%	1,106.46%	994.33%	699.48%	623.99%
Earnings before Interest and Taxes (EBIT)	-100	-105	-92	-104	986	-125	-107	-127	-117	-122	-110
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-97	-104	-93	-105	984	-129	-107	-128	-117	-122	-110
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.56	1.53	2.20	3.71	1.55	1.22	1.14	1.41	1.82	1.33	1.79
Price to Tangible Book Value (P/TBV)	1.56	1.53	2.20	3.71	1.55	1.22	1.14	1.41	1.82	1.33	1.79
Price to Revenue (P/Rev)	57.41	46.40	55.58	78.20	76.90	51.35	45.33	47.13	52.07	29.38	30.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	3.75	2.78	2.52	2.96	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	26.68%	35.95%	39.67%	33.75%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	35.09	94.14	31.05	118.49	0.00	38.32	6.07	19.46	39.63	14.75	14.72
Enterprise Value to Revenue (EV/Rev)	21.11	16.34	31.29	57.58	26.38	9.37	6.86	14.36	24.00	7.83	14.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.52	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.52	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.98	-1.00	-0.97	-0.98	-1.01	-0.99	-0.97	-0.98	-1.00	-0.99	-0.96
Leverage Ratio	1.13	1.14	1.12	1.14	1.11	1.11	1.09	1.11	1.09	1.08	1.06
Compound Leverage Factor	1.03	1.04	1.02	1.05	1.13	0.92	0.92	0.98	0.97	0.96	0.96
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.33	5.33	8.32	11.72	11.62	9.48	11.61	11.55	13.93	9.07	15.43
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.06	12.27	12.84	10.09	8.99	11.90	18.50	14.48	13.82	11.46	14.19
Quick Ratio	11.10	11.47	11.64	9.16	8.44	11.06	17.12	13.41	12.81	10.52	12.80
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-61	-75	-68	-72	-49	-92	-87	-104	-143	-105	-99
Operating Cash Flow to CapEx	0.00%	-30,977.78%	-98,878.22%	-45,942.41%	-20,099.76%	-13,771.15%	-14,554.70%	-8,814.17%	-5,668.87%	-8,590.45%	-15,464.24%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.02	0.03	0.03	0.02	0.03	0.03	0.04	0.03	0.04	0.05
Accounts Receivable Turnover	7.10	10.70	11.24	10.41	15.31	10.55	10.90	9.35	11.00	7.36	6.78
Inventory Turnover	0.24	0.21	0.17	0.17	0.16	0.18	0.18	0.18	0.20	0.21	0.20
Fixed Asset Turnover	1.14	1.40	1.65	1.93	2.30	2.70	2.94	3.51	3.98	4.81	6.11
Accounts Payable Turnover	0.23	0.20	0.30	0.31	0.23	0.32	0.37	0.35	0.31	0.36	0.48
Days Sales Outstanding (DSO)	51.40	34.13	32.47	35.05	23.84	34.60	33.49	39.06	33.19	49.61	53.82
Days Inventory Outstanding (DIO)	1,512.97	1,746.32	2,127.97	2,163.56	2,284.67	2,045.93	2,079.43	2,070.03	1,863.34	1,741.19	1,794.54
Days Payable Outstanding (DPO)	1,596.27	1,798.77	1,224.31	1,183.22	1,589.96	1,157.79	982.22	1,041.61	1,169.58	1,006.64	762.09
Cash Conversion Cycle (CCC)	-31.90	-18.32	936.13	1,015.40	718.55	922.73	1,130.70	1,067.48	726.96	784.15	1,086.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	14	4.66	30	15	-34	8.93	42	30	27	29	64
Invested Capital Turnover	1.25	6.33	1.06	1.92	-3.37	5.37	1.04	1.80	-13.09	2.87	1.25
Increase / (Decrease) in Invested Capital	-9.69	0.84	4.03	-2.10	-48	4.27	12	15	61	20	22
Enterprise Value (EV)	507	438	920	1,803	867	342	254	587	1,075	423	937
Market Capitalization	1,380	1,245	1,634	2,448	2,528	1,874	1,679	1,926	2,332	1,587	1,982
Book Value per Share	$15.91	$14.51	$13.19	$11.63	$28.59	$27.02	$25.60	$23.65	$22.10	$20.46	$18.93
Tangible Book Value per Share	$15.91	$14.51	$13.19	$11.63	$28.59	$27.02	$25.60	$23.65	$22.10	$20.46	$18.93
Total Capital	887	811	744	661	1,627	1,541	1,467	1,370	1,284	1,193	1,109
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-872	-806	-714	-645	-1,661	-1,532	-1,425	-1,339	-1,257	-1,164	-1,045
Capital Expenditures (CapEx)	-0.81	0.23	0.10	0.16	0.42	0.97	0.77	0.88	1.56	1.12	0.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.56	-11	14	-0.40	-50	-9.27	23	10	5.49	5.42	39
Debt-free Net Working Capital (DFNWC)	646	766	612	569	955	884	916	949	958	860	776
Net Working Capital (NWC)	646	766	612	569	955	884	916	949	958	860	776
Net Nonoperating Expense (NNE)	21	22	17	22	-1,045	9.00	15	23	22	23	22
Net Nonoperating Obligations (NNO)	-872	-806	-714	-645	-1,661	-1,532	-1,425	-1,339	-1,257	-1,164	-1,045
Total Depreciation and Amortization (D&A)	2.70	1.01	-1.18	-1.02	-2.39	-4.25	-0.07	-1.16	-0.30	-0.49	0.22
Debt-free, Cash-free Net Working Capital to Revenue	-6.50%	-41.19%	47.43%	-1.28%	-152.17%	-25.39%	61.77%	24.75%	12.26%	10.03%	58.99%
Debt-free Net Working Capital to Revenue	2,688.00%	2,855.31%	2,081.20%	1,819.11%	2,904.50%	2,423.27%	2,474.01%	2,321.84%	2,139.61%	1,591.48%	1,174.90%
Net Working Capital to Revenue	2,688.00%	2,855.31%	2,081.20%	1,819.11%	2,904.50%	2,423.27%	2,474.01%	2,321.84%	2,139.61%	1,591.48%	1,174.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.64)	($1.71)	($1.45)	($1.69)	$16.65	($1.65)	($1.55)	($1.93)	($1.78)	($1.86)	($1.69)
Adjusted Weighted Average Basic Shares Outstanding	55.80M	55.65M	56.38M	56.80M	56.94M	56.81M	57.46M	57.93M	58.14M	57.97M	58.78M
Adjusted Diluted Earnings per Share	($1.64)	($1.71)	($1.45)	($1.69)	$16.22	($1.44)	($1.55)	($1.93)	($1.78)	($1.86)	($1.69)
Adjusted Weighted Average Diluted Shares Outstanding	55.80M	55.65M	56.38M	56.80M	58.43M	57.89M	57.46M	57.93M	58.14M	57.97M	58.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	55.89M	56.19M	56.77M	56.89M	57.03M	57.30M	57.92M	58.10M	58.31M	58.59M	59.47M
Normalized Net Operating Profit after Tax (NOPAT)	-71	-74	-64	-74	-97	-88	-75	-89	-82	-85	-77
Normalized NOPAT Margin	-954.56%	-1,047.36%	-787.04%	-859.80%	-1,086.07%	-815.71%	-855.38%	-714.08%	-635.16%	-426.23%	-371.24%
Pre Tax Income Margin	-1,234.27%	-1,350.70%	-1,015.79%	-1,115.71%	11,167.28%	-967.06%	-1,037.61%	-903.60%	-803.05%	-537.28%	-477.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key trends for Agios Pharmaceuticals (NASDAQ: AGIO) based on quarterly data from 2022 through 2025. The company has shown top-line growth in 2025 but continues to post operating losses with negative cash flow from operations. Liquidity remains reasonable due to steady cash on hand and recurring cash inflows from investing activities, while large R&D and SG&A spend keeps margins under pressure.

Revenue growth in 2025, culminating in Q4 2025 near $20M: Operating revenue rose to $19.97M in Q4 2025, up from roughly $12–13M in the preceding quarters, marking a notable year-end uptick.
Strong quarterly investing cash inflows in 2025: Net cash from continuing investing activities was roughly $78–113M per quarter (e.g., Q1 2025 ~$112.6M, Q2 2025 ~$78.97M, Q3 2025 ~$95.56M, Q4 2025 ~$90.08M), driven by sales/maturities of investments.
Healthy liquidity shown by cash on hand: Cash and cash equivalents were about $92.7M in Q3 2025 and hovered in the $70–110M range across 2024–2025, supporting ongoing operations and R&D needs.
Gross profit remains positive in recent quarters: Q4 2025 gross profit was ~$18.1M, with Q3 2025 at ~$11.2M, indicating core revenue contributes to gross margins despite high operating costs.
Modest financing inflows in late 2025: Net cash from financing activities was modestly positive (around $2.6M) in Q3 and Q4 2025, providing some liquidity support without relying solely on operating cash flow.
High R&D and SG&A expenses relative to revenue: In Q4 2025, R&D was about $88.1M and SG&A around $51.6M, contributing to ongoing operating losses typical for a biotech in a development phase.
Quarterly revenue exhibits some variability: Revenue fluctuates across quarters (e.g., 2022–2025 patterns), reflecting typical biotechnology portfolio timing and trial-related activity.
Net income losses across all 2025 quarters: Net income declined to roughly -$89M to -$112M per quarter, with Q4 2025 reporting -$108.0M; diluted EPS in Q4 2025 was -$1.86.
Operating income consistently negative in 2025: Total operating income ran in the -$106M to -$127M range across Q1–Q4 2025 (e.g., Q4 2025 -$121.6M).
Negative cash flow from operating activities in 2025: Net cash from continuing operating activities was negative for all four 2025 quarters (e.g., Q4 2025 about -$96.2M).

05/07/26 07:06 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Agios Pharmaceuticals' Financials

When does Agios Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Agios Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Agios Pharmaceuticals' net income changed over the last 10 years?

Agios Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$412.78 million in 2025, rising from -$117.73 million in 2015. The previous period was $673.73 million in 2024. Find out what analysts predict for Agios Pharmaceuticals in the coming months.

What is Agios Pharmaceuticals' operating income?

Agios Pharmaceuticals' total operating income in 2025 was -$472.13 million, based on the following breakdown:

Total Gross Profit: $47.68 million
Total Operating Expenses: $519.82 million

How has Agios Pharmaceuticals' revenue changed over the last 10 years?

Over the last 10 years, Agios Pharmaceuticals' total revenue changed from $59.12 million in 2015 to $54.03 million in 2025, a change of -8.6%.

How much debt does Agios Pharmaceuticals have?

Agios Pharmaceuticals' total liabilities were at $104.11 million at the end of 2025, a 14.8% decrease from 2024, and a 38.9% increase since 2015.

How much cash does Agios Pharmaceuticals have?

In the past 10 years, Agios Pharmaceuticals' cash and equivalents has ranged from $70.50 million in 2018 to $203.13 million in 2021, and is currently $89.13 million as of their latest financial filing in 2025.

How has Agios Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Agios Pharmaceuticals' book value per share changed from 9.17 in 2015 to 20.46 in 2025, a change of 123.2%.

Related Companies

Financial statements for NASDAQ:AGIO last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Agios Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Financials

Annual Income Statements for Agios Pharmaceuticals

Quarterly Income Statements for Agios Pharmaceuticals

Annual Cash Flow Statements for Agios Pharmaceuticals

Quarterly Cash Flow Statements for Agios Pharmaceuticals

Annual Balance Sheets for Agios Pharmaceuticals

Quarterly Balance Sheets for Agios Pharmaceuticals

Annual Metrics And Ratios for Agios Pharmaceuticals

Quarterly Metrics And Ratios for Agios Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Agios Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools